JP2009504676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504676A5 JP2009504676A5 JP2008526279A JP2008526279A JP2009504676A5 JP 2009504676 A5 JP2009504676 A5 JP 2009504676A5 JP 2008526279 A JP2008526279 A JP 2008526279A JP 2008526279 A JP2008526279 A JP 2008526279A JP 2009504676 A5 JP2009504676 A5 JP 2009504676A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- conhs
- compound according
- size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003003 spiro group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 229940125844 compound 46 Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- MXZWCVKSYUXGOK-UHFFFAOYSA-N CC(C)(CN(CC1)CCN1C1=Nc(cccc2)c2Nc2c1cc(C)[s]2)C(O)=O Chemical compound CC(C)(CN(CC1)CCN1C1=Nc(cccc2)c2Nc2c1cc(C)[s]2)C(O)=O MXZWCVKSYUXGOK-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1c(*)c(C(N2CCN(CC(*)(*)*)CC2)=Nc(cc(*)c(*)c2)c2N2)c2[s]1 Chemical compound Cc1c(*)c(C(N2CCN(CC(*)(*)*)CC2)=Nc(cc(*)c(*)c2)c2N2)c2[s]1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70736805P | 2005-08-11 | 2005-08-11 | |
| US11/502,789 US7807828B2 (en) | 2005-08-11 | 2006-08-10 | Olanzapine analogs and methods of use thereof |
| PCT/US2006/031602 WO2007022068A1 (en) | 2005-08-11 | 2006-08-11 | Olanzapine analogs and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504676A JP2009504676A (ja) | 2009-02-05 |
| JP2009504676A5 true JP2009504676A5 (enExample) | 2009-09-24 |
Family
ID=37460090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008526279A Pending JP2009504676A (ja) | 2005-08-11 | 2006-08-11 | オランザピンアナログ及びその使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7807828B2 (enExample) |
| EP (1) | EP1915379B1 (enExample) |
| JP (1) | JP2009504676A (enExample) |
| AT (1) | ATE448234T1 (enExample) |
| CA (1) | CA2617107C (enExample) |
| DE (1) | DE602006010400D1 (enExample) |
| ES (1) | ES2333983T3 (enExample) |
| WO (1) | WO2007022068A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| WO2007092333A1 (en) * | 2006-02-03 | 2007-08-16 | Hypnion, Inc. | Use of olopatadine for treating sleep disorders |
| EP2077860B1 (en) | 2006-10-25 | 2014-04-09 | Ramot at Tel-Aviv University Ltd | Psychotropic agents having glutamate nmda activity |
| AU2008335788B2 (en) * | 2007-12-12 | 2012-11-29 | Amgen Inc. | Glycine transporter-1 inhibitors |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| PL395468A1 (pl) | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Zwiazki amidoalkilopiperazynylowe do leczenia chorób osrodkowego ukladu nerwowego |
| NO2729474T3 (enExample) * | 2011-07-08 | 2018-08-11 | ||
| BR112014004557A2 (pt) * | 2011-08-30 | 2017-05-30 | Lilly Co Eli | compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ila como agonistas inversos de h1/antagonistas de 5-ht2a de dupla atividade |
| HUE037363T2 (hu) | 2013-01-14 | 2018-08-28 | Lilly Co Eli | Kettõs aktivitású H1 inverz agonista/5-HT2A antagonista (tieno[2,3-b][1,5]-benzoxazepin-4-il)piperazin-1-il vegyületek |
| TW201625644A (zh) | 2014-04-29 | 2016-07-16 | 美國禮來大藥廠 | 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物 |
| EP3735223A4 (en) * | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
| CN114929688B (zh) * | 2019-10-21 | 2024-11-01 | 阿莱瑞恩公司 | 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物 |
| CN114685527B (zh) * | 2020-12-25 | 2024-03-05 | 长沙博源医疗科技有限公司 | 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04211071A (ja) * | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
| US5602124A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| US5744470A (en) * | 1996-03-11 | 1998-04-28 | Eli Lilly And Company | Method for treating insomnia |
| AU739385B2 (en) | 1997-09-02 | 2001-10-11 | Mitsubishi Pharma Corporation | Condensed thiophene compounds and pharmaceutical use thereof |
| US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| US20050009730A1 (en) * | 2001-10-16 | 2005-01-13 | Dale Edgar | Treatment of cns disorders using cns target modulators |
| CA2536107A1 (en) | 2003-09-09 | 2005-03-24 | Eli Lilly And Company | Substituted piperazines of azepines, oxazepines, and thiazepines |
-
2006
- 2006-08-10 US US11/502,789 patent/US7807828B2/en not_active Expired - Fee Related
- 2006-08-11 EP EP06801404A patent/EP1915379B1/en not_active Expired - Lifetime
- 2006-08-11 WO PCT/US2006/031602 patent/WO2007022068A1/en not_active Ceased
- 2006-08-11 CA CA2617107A patent/CA2617107C/en not_active Expired - Fee Related
- 2006-08-11 JP JP2008526279A patent/JP2009504676A/ja active Pending
- 2006-08-11 AT AT06801404T patent/ATE448234T1/de not_active IP Right Cessation
- 2006-08-11 ES ES06801404T patent/ES2333983T3/es not_active Expired - Lifetime
- 2006-08-11 DE DE602006010400T patent/DE602006010400D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539267A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2010530897A5 (enExample) | ||
| JP2009535462A5 (enExample) | ||
| JP2010526777A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2011510079A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2010523692A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| MX2009009492A (es) | Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas. | |
| JP2006143751A5 (enExample) | ||
| JP2007534702A5 (enExample) | ||
| JP2008539268A5 (enExample) | ||
| JP2007302689A5 (enExample) | ||
| JP2009538861A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2014518212A5 (ja) | 化合物及び組成物 | |
| JP2012509265A5 (enExample) |